重组链激酶与尿激酶治疗急性心肌梗死的疗效分析

Intravenous thrombolytic therapy with Urokinase(UK) and recombinant streptokinase(r-SK) in patients with acute myocardial infarction

目的 评价国产重组链激酶 (r-SK)与尿激酶 (UK)治疗急性心肌梗死 (AMI)的疗效 ,并比较二者的差异。方法 1 4 6例AMI患者均采用静脉溶栓 ,分为UK治疗组 (71例 )和r-SK治疗组 (75例 )。结果 溶栓治疗后 ,梗死相关血管再通率r-SK组为 72 0 % (54/ 75) ,UK组为 63 38% (45/ 71 ) ,P <0 0 5差异显著 ;r-SK组住CCU时间及住院时间均低于UK组 (P<0 0 5) ;30d病死率r-SK组为 5 33 % (4/ 75) ,UK组为 5 63 % (4/ 71 ) ,差异不显著 (P >0 0 5) ;两组均未出现严重出血及其他并发症。但r-SK组过敏反应发生率为 8 0 % (6/ 75) ,低血压发生率为 2 67% (2 / 75)。结论 使用国产r -SK加速法治疗AMI,梗死相关血管再通率高于UK ,病人住CCU时间和平均住院时间缩短 ,30d病死率与UK相似 ,但过敏反应及低血压发生率r-SK较UK高 ,国产r-SK治疗AMI无严重出血 ,疗效确实 。

Objective To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using Urokinase(UK)and recombinant streptokinase(r-SK)in patients with acute myocardial infarction (AMI).Methods 146 patients were divided into UK group (71 cases)and r-SK group(75 cases).Results The reperfusion rates of infarct-related arteries in UK and r-SK groups were 63.38%(45/71)and 72.0%(54/75), P <0.05.There was significant reduction in the time of CCU and mean hospital days in r-SK group compared with UK group ( P <0.05).The total 30 days mortality in r-SK and UK groups were 5.33%(4/75)and 5.63%(4/71), P >0.05.Two groups no severe bleeding and complications,the hypotension and incidence of allergic reaction in r-SK group was 2.67%(2/75)and 8.0%(6/75).Conclusion The r-SK is effective,reliable and safe thrombolytic agents for AMI.